ALPHAMAB ONCOLOGY announced that abstracts and posters of six different research updates on KN046 and KN026 will be presented at the 2023 congress of European Society for Medical Oncology, an influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO Congress 2023 will take place from October 20, 2023 to October 24, 2023, local time, in Madrid, Spain, whereby the latest cutting-edge data from all around the world will be disseminated. KN046 is a global innovative PD-L1/CTLA-4 bispecific antibody independently developed by the Group, targeting both PD-L1 and CTLA-4 with a clear structural differentiation to improve localization with the tumor microenvironment and to reduce off-target toxicity.

Approximately 20 clinical trials of KN046 in different stages covering more than 10 types of tumors including NSCLC, triple-negative BC, esophageal squamous cell carcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma and thymic carcinoma have been conducted in China, the United States of America and Australia. The results of these clinical trials have demonstrated a preliminary profile of good safety and promising efficacy of KN046. Among them, the preliminary results of phase II clinical trials in China indicate promising activity of KN046 for NSCLC, pancreatic ductal adenocarcinoma, hepatocellular carcinoma and triple-negative BC as a single therapy and in combination therapy with chemotherapy.

The Group has published preliminary promising safety and efficacy data of KN046 in patients who have failed prior treatments with immune checkpoint inhibitors. The Group is conducting pivotal clinical trials in NSCLC and pancreatic ductal adenocarcinoma. The Group is also exploring cooperation opportunities to conduct clinical trials of KN046 in combination with its business partners' drug candidates, to achieve better therapeutic effects.

The preclinical and clinical trial results of KN046 have shown promising efficacy and indicated that KN046 is able to significantly reduce toxicity to human peripheral system. The Company believes that KN046 has the potential to become a breakthrough in cancer immunotherapy. KN026 was designed to be a global-level next-generation HER2-targeted therapy.

With its innovative structure, it binds simultaneously to 2 distinct clinically validated epitopes of HER2 (paratope II and IV), and maintains a wild type Fc region. This results in (i) a dual blockade of HER2-related signaling pathways, (ii) strengthened binding to HER2 receptors, (iii) a reduction of HER2 proteins on the cell surface, and (iv) increased tumor killing effect through intact antibody dependent cell-mediated cytotoxicity. These binding mechanisms enable KN026 to have excellent tumor suppressive effect.

Several phase I/II clinical trials of KN026 have shown good preliminary efficacy in patients with advanced HER2-positive BC and GC/GEJ. Currently, two phase III clinical trials of KN026 as second-line or above treatment of HER2-positive GC/GEJ and as first- line treatment of HER2-positive BC are ongoing in China.